Share via Email

* Email To: (Separate multiple addresses with a semicolon)
* Your Name:
* Email From: (Your IP Address is
* Email Subject: (personalize your subject)

Email Content: Poultry Industry News, Comments and more by Simon M. Shane

Zoetis Posts Q3 Results


On November 4th, Zoetis Inc (ZTS) posted results for the third quarter ending September 30th. For the period, the company earned $552 million on revenue of $1,990 million with an EPS of $1.16.  For the comparable third quarter of fiscal 2020, the company earned $479 million on revenue of $1,786 million with an EPS of $1.00.


In commenting on results, Kristin Peck, CEO stated, "we delivered strong results again this quarter with ten percent operational growth for both revenue and adjusted net income driven by our innovative portfolio of pet care, parasiticides, and dermatology products".  The executive commentary dwelt entirely on companion species including market acceptability of monoclonal antibody therapy for osteoarthritis. Zoetis increased guidance with anticipate revenue for fiscal 2021 between $7.70 billion and $7.75 billion.  Diluted EPS will range from $4.23 to $4.29.


In reviewing revenue as to source, the U.S. represented 53.5 percent and the international market 45.4 percent.  Companion animal products represented 60.0 percent of revenue compared to 55.7 percent in Q3 of 2020.


Of the $767 million revenue from livestock, poultry represented 16.2 percent unchanged from the corresponding quarter in Q3 2020.  Poultry products including vaccines, pharmaceuticals and Embrex in ovo vaccination equipment and services represented 6.2 percent of total Zoetis revenue for the quarter.


Zoetis posted an operating margin across all products of 36.2 percent and a profit margin of 25.8 percent.  The company generated a return on assets of 12.4 percent and 51.9 percent on equity.

Copyright © 2022 Simon M. Shane